Effects of Silymarin Combined with Herbal Medicine on Th17/Treg Cell Imbalance and Inflammatory Response in Patients with Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Hepatitis Monthly · 11.08.2025 · 25 (1)
DOI: 10.5812/hepatmon-157416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatitis Monthly, online erschienen am 11.08.2025. Verfasst von Meiqing Mai und 6 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Nonalcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), is a globally prevalent chronic liver condition with a poor prognosis if it progresses to nonalcoholic steatohepatitis (NASH). Silymarin, a flavonoid complex derived from Silybum marianum, exhibits anti-inflammatory and hepatoprotective properties. However, limited research exists on its combined use with traditional Chinese medicines (TCMs), such as Pueraria lobata, Salvia miltiorrhiza, and Schisandra chinensis, for NAFLD treatment.
Objectives
The present study aimed to evaluate the therapeutic effects of silymarin combined with TCM and silymarin alone in patients with NAFLD.
Methods
In this randomized, double-blind, placebo-controlled trial, 94 NAFLD patients were allocated to three groups: Silymarin + TCM (n = 32), silymarin alone (n = 31), or placebo (n = 31) for 12 weeks. Primary outcomes included liver enzyme levels and lipid profiles. Secondary outcomes comprised Th17/Treg cell ratios in peripheral blood and mRNA expression of NLRP3 inflammasome-related genes in peripheral blood mononuclear cells (PBMCs).
Results
After 12 weeks, the silymarin + TCM group showed a 48.01% reduction in serum interleukin (IL)-18 (P < 0.05), decreased Th17 cell proportions (P < 0.05), and a reduced Th17/Treg ratio (P < 0.01). Both silymarin + TCM and silymarin alone significantly downregulated mRNA expression of NLRP3 (P < 0.01, P < 0.05), CASP1 (P < 0.001, P < 0.01), and IL1B (P < 0.001, P < 0.05) in PBMCs. IL18 mRNA expression was notably lower in the silymarin + TCM group compared to the placebo group (P < 0.01).
Conclusions
The combination of silymarin with P. lobata, S. miltiorrhiza, and S. chinensis modulates Th17/Treg balance and suppresses NLRP3 inflammasome activation, potentially attenuating inflammatory progression in NAFLD. This regimen offers a safe and cost-effective therapeutic strategy for NAFLD management.
Zitieren
APA
Mai, M., Wang, Y., Wang, D., Ruan, Y., Mo, B., Li, Z., & Guo, H. (2025). Effects of Silymarin Combined with Herbal Medicine on Th17/Treg Cell Imbalance and Inflammatory Response in Patients with Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Hepatitis Monthly, 25(1). https://doi.org/10.5812/hepatmon-157416
Vancouver
Mai M, Wang Y, Wang D, Ruan Y, Mo B, Li Z, et al. Effects of Silymarin Combined with Herbal Medicine on Th17/Treg Cell Imbalance and Inflammatory Response in Patients with Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Hepatitis Monthly. 2025;25(1). doi:10.5812/hepatmon-157416
BibTeX
@article{Mai2025,
author = {Mai, Meiqing and Wang, Ya and Wang, Di and Ruan, Yongdui and Mo, Bingquan and Li, Zhongxia and Guo, Honghui},
title = {Effects of Silymarin Combined with Herbal Medicine on Th17/Treg Cell Imbalance and Inflammatory Response in Patients with Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial},
journal = {Hepatitis Monthly},
year = {2025},
volume = {25},
number = {1},
doi = {10.5812/hepatmon-157416}
}
EUVIMED